keyword
MENU ▼
Read by QxMD icon Read
search

ABO incompatibility

keyword
https://www.readbyqxmd.com/read/29770457/abo-genotyping-with-next-generation-sequencing-to-resolve-heterogeneity-in-donors-with-serology-discrepancies
#1
Ping Chun Wu, Yin-Hung Lin, Lei Fang Tsai, Ming Hung Chen, Pei-Lung Chen, Shun-Chung Pai
BACKGROUND: ABO subtypes are characterized by the alteration of antigens present and their expression levels on red blood cells and many are linked to genetic changes in the ABO gene. Weakened expression of antigens should be identified to prevent transfusion reactions or ABO-incompatible transplantations. Genotyping can be applied to identify subtypes to complement serologic testing. Next-generation sequencing (NGS) has shown to provide sensitive and accurate genotyping results as well as valuable cis/trans information...
May 16, 2018: Transfusion
https://www.readbyqxmd.com/read/29760372/a-review-of-induction-with-rabbit-antithymocyte-globulin-in-pediatric-heart-transplant-recipients
#2
Martin Schweiger, Andreas Zuckermann, Andres Beiras-Fernandez, Michael Berchtolld-Herz, Udo Boeken, Jens Garbade, Stephan Hirt, Manfred Richter, Arjang Ruhpawar, Jan Dieter Schmitto, Felix Schönrath, Rene Schramm, Uwe Schulz, Markus J Wilhelm, Markus J Barten
Pediatric heart transplantation (pHTx) represents only a small proportion of cardiac transplants. Due to these low numbers, clinical data relating to induction therapy in this special population are far less extensive than for adults. Induction is used more widely in pHTx than in adults, mainly because of early steroid withdrawal or complete steroid avoidance. Antithymocyte globulin (ATG) is the most frequent choice for induction in pHTx, and rabbit antithymocyte globulin (rATG, Thymoglobulin®) (Sanofi Genzyme) is the most widely-used ATG preparation...
May 15, 2018: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/29731097/desensitization-with-the-use-of-an-antibody-removal-free-protocol-in-abo-incompatible-kidney-transplant-recipients-with-a-low-anti-a-b-antibody-titer
#3
K Nanmoku, T Shinzato, T Kubo, T Shimizu, T Kimura, T Yagisawa
BACKGROUND: Desensitization for ABO-incompatible (ABOi) kidney transplantation mainly comprises removal of antibodies with the use of apheresis and suppression of antibody (Ab) production with the use of rituximab. This study aimed to estimate the outcomes of ABOi kidney transplantation with the use of an Ab removal-free protocol to avoid complications associated with apheresis. METHODS: A total of 32 de novo consecutive adults who underwent ABOi living-donor kidney transplantation were retrospectively evaluated...
May 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29731066/distribution-of-anti-abo-immunoglobulin-g-subclass-and-c1q-antibody-in-abo-incompatible-kidney-transplantation
#4
K H Lee, D I Won, J-M Yook, K Y Kim, S M Park, J H Park, E S Lee, J-H Lim, H-Y Jung, J-Y Choi, S-H Park, C-D Kim, Y-L Kim, H-K Kim, S Huh, J-H Cho
INTRODUCTION: To investigate the correlation between serum anti-ABO immunoglobulin G (IgG) and IgG subclasses, anti-ABO IgG subclasses were measured by flow cytometry (FCM) in ABO-incompatible (ABOi) kidney transplant recipients. We also evaluated baseline anti-ABO C1q antibody. METHOD: Baseline anti-ABO IgG titers were measured by both FCM and column agglutination technique methods in 18 ABOi kidney transplant recipients. The mean florescence intensity (MFI) ratios of baseline anti-ABO IgG subclasses and anti-ABO C1q antibody were obtained by FCM and followed-up after rituximab treatment, each plasmapheresis (PP) session, and kidney transplantation...
May 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29731065/vdj-gene-usage-of-b-cell-receptors-in-peripheral-blood-of-abo-incompatible-kidney-transplantation-patients
#5
H J Jeon, T Fang, J-G Lee, J Y Jang, K Kim, S Choi, J-J Yan, J H Ryu, T Y Koo, C Ahn, J Yang
INTRODUCTION: B cell subtypes and immunoglobulin variable (V), diversity (D), joining (J) gene segment usage of B cell receptors in ABO-incompatible (ABOi) kidney transplantation (KT) in comparison to ABO-compatible KT have not been studied. The aims of this study were to analyze the VDJ gene segment usages of B cell receptors in peripheral blood of ABOi KT recipients. METHODS: Eighteen ABOi KT patients with accommodation (ABOiA), 10 ABO-compatible stable KT patients (ABOcS), and 10 ABOi KT patients with biopsy-proven acute antibody-mediated rejection (ABOiR) at day 10 after transplantation were selected...
May 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29724631/transfusion-policy-in-allogeneic-hematopoietic-stem-cell-transplantation
#6
REVIEW
Pervin Topcuoglu
The incompatibility of ABO blood group between the recipient and the donor is not a barrier to perform allogeneic hematopoietic stem cell transplantation (Allo-HSCT). However, ABO incompatibility may lead to many complications during and after stem cell transplantation at the early or late period. Therefore, the typing of the blood group of the recipient and the donor should be done prior to the transplantation. In addition, the ABO/Rh group of blood products for transfusion should be determined according to the type of ABO-incompatibility...
April 18, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29724627/graft-failure-after-allogeneic-hematopoietic-stem-cell-transplantation
#7
REVIEW
Zehra Narli Ozdemir, Sinem Civriz Bozdağ
Graft failure is a serious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) defined as either lack of initial engraftment of donor cells (primary graft failure) or loss of donor cells after initial engraftment (secondary graft failure). Successful transplantation depends on the formation of engrafment, in which donor cells are integrated into the recipient's cell population. In this paper, we distinguish two different entities, graft failure (GF) and poor graft function (PGF), and review the current comprehensions of the interactions between the immune and hematopoietic compartments in these conditions...
April 18, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29710397/is-portal-venous-pressure-modulation-still-indicated-for-all-recipients-in-living-donor-liver-transplantation
#8
Siyuan Yao, Toshimi Kaido, Ryuji Uozumi, Shintaro Yagi, Yosuke Miyachi, Ken Fukumitsu, Takayuki Anazawa, Naoko Kamo, Kojiro Taura, Hideaki Okajima, Shinji Uemoto
BACKGROUND: There is a consensus that portal venous pressure (PVP) modulation prevents portal hypertension (PHT) and consequent complications after adult living donor liver transplantation (ALDLT). However, PVP-modulation strategies need updating based on most recent findings. We examined our 10-year experience of PVP modulation and reevaluate whether it is necessary for all recipients or selected recipients in ALDLT. METHODS: In this retrospective study, 319 patients who underwent ALDLT from 2007 to 2016 were divided into three groups according to the necessity and results of PVP modulation: not indicated (n=189), indicated and successful (n=92), and indicated but failed (n=38)...
April 30, 2018: Liver Transplantation
https://www.readbyqxmd.com/read/29709370/development-of-models-to-predict-early-post-transplant-recurrence-of-hepatocellular-carcinoma-that-also-integrate-the-quality-and-characteristics-of-the-liver-graft-a-national-registry-study-in-china
#9
Qi Ling, Jimin Liu, Jianyong Zhuo, Runzhou Zhuang, Haitao Huang, Xiangxiang He, Xiao Xu, Shusen Zheng
BACKGROUND: Donor characteristics and graft quality were recently reported to play an important role in the recurrence of hepatocellular carcinoma after liver transplantation. Our aim was to establish a prognostic model by using both donor and recipient variables. METHODS: Data of 1,010 adult patients (training/validation: 2/1) undergoing primary liver transplantation for hepatocellular carcinoma were extracted from the China Liver Transplant Registry database and analyzed retrospectively...
April 27, 2018: Surgery
https://www.readbyqxmd.com/read/29703920/prevalent-metabolic-derangement-and-severe-thrombocytopenia-in-abo-incompatible-liver-recipients-with-pre-transplant-plasma-exchange
#10
Hye-Mee Kwon, In-Gu Jun, JungBok Lee, Young-Jin Moon, Kyeo-Woon Jung, Hye-Won Jeong, Yong-Seok Park, Jun-Gol Song, Gyu-Sam Hwang
Desensitisation with therapeutic plasma exchange (TPE) is essential for ABO-incompatible (ABO-I) liver transplants (LTs). However, excessive citrate load and coagulation disturbances after TPE have been poorly studied, in particular in cirrhotic patients with hypocapnic alkalosis, metabolic compensation and electrolyte imbalances. We retrospectively evaluated 1123 consecutive LT recipients (923 ABO-compatible [ABO-C], 200 ABO-I) from November 2008 to May 2015. TPE was generally performed a day before LT and blood sampling was performed before anaesthesia induction...
April 27, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29700043/enhancement-of-red-blood-cell-transfusion-compatibility-using-crispr-mediated-erythroblast-gene-editing
#11
Joseph Hawksworth, Timothy J Satchwell, Marjolein Meinders, Deborah E Daniels, Fiona Regan, Nicole M Thornton, Marieangela C Wilson, Johannes Gg Dobbe, Geert J Streekstra, Kongtana Trakarnsanga, Kate J Heesom, David J Anstee, Jan Frayne, Ashley M Toye
Regular blood transfusion is the cornerstone of care for patients with red blood cell (RBC) disorders such as thalassaemia or sickle-cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR-mediated genome editing of an immortalised human erythroblast cell line (BEL-A) to generate multiple enucleation competent cell lines deficient in individual blood groups. Edits are combined to generate a single cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rhnull ), Kell ( K 0 ), Duffy (Duffynull ), GPB (S- s- U- )...
April 26, 2018: EMBO Molecular Medicine
https://www.readbyqxmd.com/read/29687886/false-negative-compatible-antiglobulin-crossmatches-in-samples-with-alloantibodies-to-cognate-red-blood-cell-antigens
#12
Christian P Nixon, Stephanie L Krohto, Joseph D Sweeney
BACKGROUND: Patient samples showing a positive indirect antiglobulin test are further tested to identify alloantibody specificity using a panel of phenotypically characterized group O reagent red blood cells (RBCs). Donor RBCs phenotypically negative for the antibody specificity are then serologically crossmatched using an antiglobulin reagent. This latter test is performed to identify any incompatibility due to the presence of undetected minor blood group antibodies and considered an important step in patient safety...
April 24, 2018: Transfusion
https://www.readbyqxmd.com/read/29686715/knowledge-level-and-determinants-of-neonatal-jaundice-a-cross-sectional-study-in-the-effutu-municipality-of-ghana
#13
Prince Adoba, Richard K D Ephraim, Kate Adomakowaah Kontor, Joseph-Josiah Bentsil, Patrick Adu, Maxwell Anderson, Samuel Asamoah Sakyi, Paul Nsiah
Background: Neonatal jaundice (NNJ) is a major cause of hospital admission during the neonatal period and is associated with significant mortality. This case-control study with cross-sectional design sought to identify the possible factors associated with neonatal jaundice and assess maternal knowledge level of this condition. Methods: One hundred and fifty (150) neonates comprising 100 with clinically evident jaundice and 50 without jaundice were conveniently recruited from the Trauma and Specialist Hospital in the Effutu Municipality...
2018: International Journal of Pediatrics
https://www.readbyqxmd.com/read/29684566/eltrombopag-for-the-treatment-of-of-refractory-pure-red-cell-aplasia-after-major-abo-incompatible-hematopoietic-stem-cell-transplantation
#14
Alessandro Busca, Chiara Dellacasa, Luisa Giaccone, Sara Manetta, Lucia Biale, Laura Godio, Semra Aydin, Moreno Festuccia, Lucia Brunello, Benedetto Bruno
Pure red cell aplasia (PRCS) is a well-recognized complication after allogeneic hematopoietic stem cell transplantation (HSCT). Many therapeutic options are available to treat this condition, including erythropoietin, rituximab, bortezomib, plasma exchange, immunoadsorption, donor lymphocyte infusion, mesenchymal stem cells, anti-thymocyte globulin and high-dose steroids; however treatment outcomes are often variable and can sometimes lead to disappointing results. In this brief article we report our experience with two patients with PRCA after major AB0-incompatible HSCT who were resistant to multiple therapeutic interventions and who eventually benefited from treatment with eltrombopag, a thrombopoietin mimetic approved by the Food and Drug Administration for the treatment of patients with immune thrombocytopenic purpura or severe aplastic anemia (SAA), refractory to immunosuppressive agents or not eligible to HSCT...
April 20, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29663666/comparison-of-outcomes-after-hla-matched-unrelated-and-%C3%AE-%C3%AE-t-cell-depleted-haploidentical-hematopoietic-stem-cell-transplantation-for-children-with-high-risk-acute-leukemia
#15
Fatih Erbey, Arzu Akçay, Didem Atay, Ercüment Ovalı, Gülyüz Öztürk
T-cell-depleted HAPLO HSCT is an option to treat children with high-risk acute leukemia lacking an HLA-identical donor. We reviewed the outcome of children with acute leukemia after HAPLO (n = 21) and HLA-MUD (n = 32) transplantation. The proportion of patients with ≥CR2 was significantly higher in HAPLO transplantation than MUD transplantation. Patients with MUD transplantation were significantly higher ABO incompatible than patients with HAPLO transplantation. There was no difference between the 2 groups in terms of engraftment, aGvHD and cGvHD, VOD, hemorrhagic cystitis, infections, and relapse...
April 16, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29661455/management-of-juvenile-idiopathic-arthritis-in-abo-incompatible-kidney-transplantation-a-case-report
#16
S Ishikawa, M Tasaki, T Kuroda, D Kobayashi, K Saito, Y Nakagawa, M Ikeda, K Takahashi, Y Tomita
Biologic agents are a beneficial therapy for juvenile idiopathic arthritis (JIA). However, there is a lack of evidence with regard to management of these agents for JIA patients who undergo kidney transplantation (KTx). A 36-year-old woman with JIA who was treated with tocilizumab targeting interleukin-6 (IL-6) receptor underwent ABO-incompatible kidney transplantation (ABOi KTx). To prevent over-immunosuppression, tocilizumab was discontinued before ABOi KTx. Rituximab, tacrolimus, mycophenolate mofetil, everolimus, and methylprednisolone were used for immunosuppression...
April 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29624682/abo-incompatibility-and-rhig-immunoprophylaxis-protect-against-non-d-alloimmunization-by-pregnancy
#17
Carolien Zwiers, Joke M Koelewijn, Lisa Vermij, Joost van Sambeeck, Dick Oepkes, Masja de Haas, C Ellen van der Schoot
BACKGROUND: Hemolytic disease of the fetus and newborn (HDFN) is caused by maternal antibodies against fetal red blood cell antigens, most often anti-D, -K, or -c. ABO incompatibility between mother and child and anti-D immunoprophylaxis (RhIG) are known to reduce the risk of D immunization and subsequent HDFN. However, no immunoprophylaxis has been developed to prevent non-D immunizations. STUDY DESIGN AND METHODS: We evaluated whether ABO incompatibility has a preventive effect on formation of non-D alloantibodies, by performing a case-control study including pregnant women with newly detected non-D antibodies, identified within a nationwide data set, immunized during their first pregnancy and/or delivery...
April 6, 2018: Transfusion
https://www.readbyqxmd.com/read/29620615/long-term-outcomes-of-abo-incompatible-pediatric-living-donor-liver-transplantation
#18
Masaki Honda, Yasuhiko Sugawara, Masashi Kadohisa, Keita Shimata, Masataka Sakisaka, Daiki Yoshii, Keiichi Uto, Shintaro Hayashida, Yuki Ohya, Hidekazu Yamamoto, Hirotoshi Yamamoto, Yukihiro Inomata, Taizo Hibi
BACKGROUND: ABO-incompatible (ABOi) living donor liver transplantation (LDLT) have been performed to compensate for donor shortage. To date, few studies have reported detailed B cell desensitization protocols and long-term outcomes of ABOi pediatric LDLT. METHODS: Twenty-nine pediatric ABOi LDLT recipients were retrospectively analyzed. We compared the clinical outcomes between ABOi (n = 29) and non-ABOi (n = 131) pediatric LDLT recipients. Furthermore, we evaluated the safety and efficacy of our rituximab-based regimen for ABOi pediatric LDLT (2 ≤ age < 18, n = 10)...
April 3, 2018: Transplantation
https://www.readbyqxmd.com/read/29608324/the-devil-is-in-the-details-retention-of-recipient-group-a-type-5-years-after-a-successful-allogeneic-bone-marrow-transplant-from-a-group-o-donor
#19
Laura L W Cooling, Michelle Herrst, Sherri L Hugan
ABO-incompatible (ABOi) hematopoietic stem cell transplants (HSCTs) can present challenges in the blood bank. During transplantation, patients receive components that are ABO-compatible with both the donor graft and recipient; this practice can strain group O red blood cell (RBC) inventories.1 In addition, there are risks for acute hemolysis at the time of infusion and in the early post-transplant period.1,2 In ABO major-incompatible bone marrow HSCTs, which contain significant quantities of donor RBCs that are ABOi with recipient plasma, it is common to perform a RBC depletion of the bone marrow in an effort to minimize hemolysis at the time of infusion...
January 2018: Immunohematology
https://www.readbyqxmd.com/read/29576278/a-comparison-of-desensitization-methods-rituximab-with-without-plasmapheresis-in-abo-incompatible-living-donor-liver-transplantation
#20
Eung Chang Lee, Seong Hoon Kim, Jae Ryong Shim, Sang-Jae Park
BACKGROUND: Plasmapheresis is a desensitization method used prior to ABO-incompatible (ABO-I) living donor liver transplantation. However, studies on its usefulness in the rituximab era are lacking. METHODS: Fifty-six adult patients underwent ABO-I living donor liver transplantation between January 2012 and October 2015. A single dose of rituximab (300 mg/m2 ) was administered 2 weeks before surgery with plasmapheresis in all patients until February 2014 (RP group, n = 26)...
February 19, 2018: Hepatobiliary & Pancreatic Diseases International: HBPD INT
keyword
keyword
107578
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"